Zevra Therapeutics (ZVRA) Other Operating Expenses (2019 - 2026)

Zevra Therapeutics' Other Operating Expenses history runs 6 years deep, the most recent figure standing at $43.3 million for Q1 2026.

• Quarterly Other Operating Expenses changed N/A year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $191.6 million (changed N/A YoY) and the FY2025 annual result came in at $148.3 million, changed N/A from the prior year.
• Other Operating Expenses was $43.3 million for Q1 2026 at Zevra Therapeutics, down from $148.3 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $148.3 million in Q2 2025 and bottomed at -$23.4 million in Q4 2022.
• A 3-year average of $31.7 million and a median of $10.9 million in 2022 frame the typical range for Other Operating Expenses.
• Peak annual rise in Other Operating Expenses reached 1669.4% in 2022, while the deepest fall reached 39822.03% in 2022.
• Zevra Therapeutics' Other Operating Expenses stood at -$23.4 million in 2022, then jumped by 732.89% to $148.3 million in 2025, then slumped by 70.8% to $43.3 million in 2026.
• Business Quant data shows ZVRA's Other Operating Expenses at $43.3 million in Q1 2026, $148.3 million in Q2 2025, and -$23.4 million in Q4 2022.